While AOD 9604 breaks down fat cells, it also improves the metabolic environment
Competing interests Authors declare that they have no competing interests
The $10 billion price rested on optimistic assumptions about Metseras future performance, estimating Pfizer would need to generate about $11 billion in revenue from the deal by 2040 nearly double Metseras current projections, Courtney Breen, an analyst at Bernstein, said
Moreover, a recent study from Guzman and colleagues (39) has shown that, in patients with T2D, treatment with a selective GCGR antagonist, LY2409021, induces a significant increase in hepatic lipid content assessed by magnetic resonance imaging, suggesting that GCGR activation is required to prevent build-up of fat in the hepatocytes
Scientific Reports , 7
Take our quiz Answer a few simple questions to help us find which program is right for you